EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient‐Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing Personalized Treatment

Hongda Zhao iD, Na Lin, Vincy Wing Sze Ho, Kang Liu, Xuan Chen, Hongwei Wu, Peter Ka-Fung Chiu, Linda Huang, Zahra Dantes, Ka-Leung Wong, Ho-Fai Chau, Ivan Ching-Ho Ko und 7 weitere

Advanced Science · 2025-04 · 12 (13)

DOI: 10.1002/advs.202414558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 07.02.2025. Verfasst von Hongda Zhao und 18 weiteren Autor:innen. Beteiligte Einrichtung: S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, 999077, China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Organoids, Precision Medicine. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Research Fund from Research Grants Council of Hong Kong.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bladder cancer (BC) is a heterogeneous disease with high recurrence rates and variable treatment responses. To address these clinical challenges, the world's first bladder cancer patient‐derived organoids (PDOs) biobank is established based on an Asian population. Thirty‐six BC‐PDOs are generated from 56 patients and demonstrated that the BC‐PDOs can replicate the histological and genomic features of parental tumors. Drug screening tests are conducted with a broad spectrum of conventional chemotherapeutic and targeted therapy drugs and identified differential drug sensitivities among the BC‐PDOs. These in vitro results are consistently supported by the PDO xenograft animal studies and patients’ clinical treatment outcomes, thereby verifying the predictive power of PDOs for drug responses in BC patients. By analyzing the genetic profiles of the PDOs, specific driver genes that correlate with drug sensitivity to two stand‐of‐care chemotherapeutics, cisplatin, and gemcitabine, are identified. Additionally, the practicality of PDOs in investigating the tumor microenvironment has been demonstrated. This study underscores the utility of PDOs in advancing the understanding of bladder cancer and the development of personalized therapeutic strategies. The BC‐PDOs biobank provides an ideal preclinical platform for supporting the development of personalized treatment strategies for BC patients. This study also provides insights into the potential mechanisms of drug resistance, paves the way for subsequent region‐specific research, and demonstrates the possibility of using PDO‐related models to direct future research in developing drugs targeting tumor microenvironments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsOrganoidsPrecision MedicineHumansAnimalsMiceAntineoplastic AgentsFemaleTumor MicroenvironmentMaleXenograft Model Antitumor AssaysCisplatin

Stichwörter der Autor:innen

bladder cancerdrug screeningorganoidspersonalized medicinetumor microenvironment

Substanzen

Antineoplastic AgentsCisplatin

Autor:innen und Institutionen

  • S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, 999077, China.
  • Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, 999077, China.
  • Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Taipa, Macao, SAR, 999078, China.
  • Invitrocue Hong Kong Ltd, Hong Kong, SAR, 999077, China.
  • Invitrocue Europe AG, 80539, Munich, Germany.
  • Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, 999077, China.

ORCID-Profile: Hongda Zhao, Jeremy Yuen-Chun Teoh

Förderung

  • General Research Fund from Research Grants Council of Hong Kong

Zitieren

APA

Zhao, H., Lin, N., Ho, V. W. S., Liu, K., Chen, X., Wu, H., Chiu, P. K., Huang, L., Dantes, Z., Wong, K. L., Chau, H. F., Ko, I. C., Wong, C. H., Leung, D. K., Yuen, S. K., Wu, D., Ding, X., Ng, C. F., & Teoh, J. Y. (2025). Patient‐Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing Personalized Treatment. Advanced Science, 12(13). https://doi.org/10.1002/advs.202414558

Vancouver

Zhao H, Lin N, Ho VWS, Liu K, Chen X, Wu H, et al. Patient‐Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing Personalized Treatment. Advanced Science. 2025;12(13). doi:10.1002/advs.202414558

BibTeX
@article{Zhao2025,
  author = {Zhao, Hongda and Lin, Na and Ho, Vincy Wing Sze and Liu, Kang and Chen, Xuan and Wu, Hongwei and Chiu, Peter Ka-Fung and Huang, Linda and Dantes, Zahra and Wong, Ka-Leung and Chau, Ho-Fai and Ko, Ivan Ching-Ho and Wong, Chris Ho-Ming and Leung, David Ka-Wai and Yuen, Steffi Kar-Kei and Wu, Dinglan and Ding, Xiaofan and Ng, Chi Fai and Teoh, Jeremy Yuen-Chun},
  title = {Patient‐Derived Bladder Cancer Organoids as a Valuable Tool for Understanding Tumor Biology and Developing Personalized Treatment},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {13},
  doi = {10.1002/advs.202414558}
}
Kostenlos starten →